Locations:
Search
Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin
Treatment assigned FDA review date in June 2025
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Long-acting antiemetics and high-dose steroids key to minimizing acute nausea
Neoadjuvant immunotherapy improves outcomes
Use of GLP-1s and improving cardiovascular health lowers risk of hematologic malignancies
Sexual disorders affect patients across all cancer types
A call for awareness about the importance of genomic testing
Discussing research into improving CAR T-cell therapy efficacy
Advertisement
Advertisement